POST Online Media Lite Edition


Hong Kong, Macau suspend Pfizer-BioNTech COVID-19 vaccine over flawed vials

Christian Fernsby |
Hong Kong and Macau suspended the use of Pfizer-BioNTech's COVID-19 vaccine on Wednesday after being informed of a packaging problem affecting one batch of vials, while stressing they did not believe there was a safety risk.

Article continues below


"For the sake of precaution, the current vaccination must be suspended during the period of investigation," Hong Kong's government said in a statement.

Both Chinese cities said their decision came after they were contacted about the issue by Fosun, the Chinese pharmaceutical company that is distributing the Pfizer-BioNTech vaccine in China.

Vials with the lot number 210102 were found to have defective packaging, authorities said.

The statements from Hong Kong and Macau did not give any details on how the packaging was defective but both said they did not believe there were any safety issues.

What to read next

Canada to receive 2m doses of AstraZeneca’s vaccine manufactured by Serum Institute of India
Australia, New Zealand receive first vaccine shipments
Canada to receive early delivery of Pfizer BioNTech coronavirus vaccine